WO2021028842A1 - A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same - Google Patents
A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same Download PDFInfo
- Publication number
- WO2021028842A1 WO2021028842A1 PCT/IB2020/057570 IB2020057570W WO2021028842A1 WO 2021028842 A1 WO2021028842 A1 WO 2021028842A1 IB 2020057570 W IB2020057570 W IB 2020057570W WO 2021028842 A1 WO2021028842 A1 WO 2021028842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- gemcitabine
- pharmaceutically acceptable
- use injectable
- stable ready
- Prior art date
Links
- LENZDBCJOHFCAS-UHFFFAOYSA-N NC(CO)(CO)CO Chemical compound NC(CO)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients which can be infused without any prior dilutions before administration.
- the present invention also relates to stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, trometh amine as stabilizing and pH modifying agent and tonicity adjusting agent, pH adjusting agents, and aqueous vehicle as other pharmaceutically acceptable excipients.
- the present invention specifically relates to method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration followed by heat treatment.
- the present invention more specifically relates to method for the preparation of stable ready-to-use injectable infusion container formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, pH adjusting, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterilization and filled into the infusion container which does not contain aluminium over-pouch as secondary packaging.
- Lyophilization or freeze-drying is often used to stabilize various pharmaceutical products, including virus vaccines, protein and peptide formulations, liposome and small-chemical drug formulation. Lyophilized formulations have to be reconstituted, usually by injecting diluent through the septum into the vial. The solution is drawn up into a new syringe, the needle changed before finally being injected into the patient. These multiple steps make the lyophilized formulation inconvenient for use and provide risk of microbiological contamination during aseptic handling.
- the stable pharmaceutical composition can be prepared without the use of freeze drying techniques.
- a stable ready-to-use injectable solution could be stored at room temperature and the composition provides easier, safer handling, storage and distribution.
- Solid formulations must be such that the entire contents are readily soluble leaving essentially no solid particles and providing the entire active ingredient as homogeneously dissolved compound.
- Gemcitabine is known as difluorodeoxycytidine, an analogue of cytosine arabinoside (ara-C) is a pyrimidine antimetabolite and it works by blocking the creation of new DNA, which results in cell death.
- Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity which is used as chemotherapy medication to treat a number of types of cancers which include breast cancer, ovarian cancer, non- small cell lung cancer, pancreatic cancer, and bladder cancer.
- Gemcitabine is 4-amino- l-(2-deoxy-2, 2-difluoro-b-D-erythro- pentofuranosyl)pyrimidin-2(lH)-one, and has the following structural formula:
- Gemcitabine free base has a molecular formula of and its hydrochloride salt having molecular formula of Gemcitabine is a white to off-white crystalline powder which melts at 287- 292°C and is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.
- the aqueous solubility of gemcitabine hydrochloride in purified water is 70.2 mg/mL.
- Conventional formulations of Gemcitabine hydrochloride consists of sodium chloride as tonicity adjuster and pH adjusting agents. This formulation is clear, colourless, sterile solution in a single-dose, premixed intravenous large volume infusion bags with an aluminium over-pouch as secondary packaging and terminally sterilized by autoclave process at 121°C for 15 minutes.
- the recommended dose for Gemcitabine is 1 g/m of body surface area and gemcitabine can be used cytostatically in the therapeutic treatment of various types of cancer.
- the administration of Gemcitabine to treat different types of cancer conditions is effected intravenously, in which case the active substance must be in the form of a solution.
- Some patent literature describes the stable ready-to-use formulations of Gemcitabine or its pharmaceutically acceptable salt comprising pH modifying agents and tonicity adjusting agents such as sodium chloride and/or solubilizer such as propylene glycol, wherein the solution composition is sterilized by filtration sterilization.
- Chinese patent No. CN 1302782 C discloses Gemcitabine hydrochloride injection solution comprising Gemcitabine hydrochloride, a solvent for injection, a stabili er and an isotonic agent, wherein the injection pH range is in between 3.6-7.5.
- EP 1 479 388 B1 discloses pharmaceutical composition including gemcitabine in the form of a ready-to-use solution concentrate, wherein the gemcitabine is dissolved in a mixture of water and at least one other physiologically acceptable solvent or solubilising agent, wherein solubilising agents are ethanol, polyethylene glycol 200 - 600 and/or 1,2-propanediol (propylene glycol).
- solubilising agents are ethanol, polyethylene glycol 200 - 600 and/or 1,2-propanediol (propylene glycol).
- the pH of the composition is in the range of 3.5 to 10.0 and gemcitabine concentration is 50 mg/ml or 80 mg/ml and solution sterilized by filtration.
- European Pat. No. EP 1 479 389 B1 discloses Gemcitabine ready-to-use solution comprising 0.05 mg/ml to 16.0 mg/ml of Gemcitabine having pH of above 3.5.
- the stability data of examples disclosed in this patent demonstrate that compositions with higher concentration of Gemcitabine (more than 16.0 mg/ml) cause precipitation when stored at lower temperatures.
- the solvent was selected from the ethyl alcohol, polyethylene glycol 200-600, propylene glycol and mixture thereof. Solution is sterilized by filtration and the filtered solution is filled into vials.
- U.S Pat. No. 9,241,948 B2 discloses large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion polymeric container covered with a secondary packaging system of aluminium over-pouch, wherein the solution is ready-to-be-infused.
- the injection dosage form is obtained by subjecting the solution filled in infusion container to terminal sterili ation by autoclave at 121°C for 15 minutes.
- U.S Pub No. US 2006/0089328 A1 discloses an injectable pharmaceutical composition
- U.S Pub No. US 2006/0154891 A1 discloses ready-to-use Gemcitabine aqueous preparation in glass container having specified dimensional relationships to demonstrate shelf life of over wide range of solution pH values.
- the ratio of surface area wetted by the composition to the volume of the solution contained in the container, expressed in cm /cm is less than 3.4.
- Gemcitabine concentration is between 0.05 mg/mL and 110 mg/mL and pH of the aqueous solution is within a range of about 5.0 to about 10.0.
- U.S Pub No. US 2012/0129799 A1 discloses stable non-aqueous pharmaceutical preparation comprising Gemcitabine or its pharmaceutically acceptable salts in a ready-to-use form comprising non-aqueous solvent, wherein non- aqueous solvent includes propylene glycol, polyethylene glycols, ethanol or the like thereof either alone or in combination thereof and the pH is between about 3.5 and about 10.0.
- PCT Pub No. WO 2007/143895 A1 discloses, stable supersaturated solution of Gemcitabine hydrochloride, which is prepared by dissolving completely Gemcitabine hydrochloride in a medium by heating it at pH 4-8 to give a supersaturated solution of Gemcitabine having a concentrate of 15-45 g/L and the hot supersaturated solution was sterilized by filtration and dispensed in ampoules.
- the commercially available product contain Gemcitabine or its pharmaceutically salt and is marketed under the trade name Gemzar ® by Eli Lilly & Co which is supplied as a sterile lyophilised powder in single-dose vials for reconstitution which has to be dissolved for intravenous infusion.
- the product formulation contains, in addition to the active ingredient, mannitol, sodium acetate and hydrochloric acid and / sodium hydroxide may have been added for pH adjustment.
- Gemzar ® upon reconstitution concentration is 40 mg/mL. It is reported that at concentrations greater than 40 mg/mL may result in incomplete dissolution, and therefore should be avoided.
- a ready-to-use solution can be filled in vial or glass container and supplied as single dose vial.
- Sterilization of injectable solution filled in the glass container plays a major role in maintaining stability and shelf life of the drug product.
- Sterilization of glass container can be achieved by many ways either by filtration sterilization, terminal sterilization by moist heat and dry heat sterilization.
- the use of stabilizer in the formulation and sterilization of infusion container are the key elements in developing a stable pharmaceutical composition of Gemcitabine or its salt.
- a stable ready-to-be-infused preparation containing Gemcitabine or its pharmaceutically acceptable salts there is a need to develop a stable ready-to-be-infused preparation containing Gemcitabine or its pharmaceutically acceptable salts.
- the inventors of the present invention have developed a stable ready-to-use injectable Gemcitabine composition comprising tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents as other pharmaceutically acceptable excipients which provide better effect for the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
- the inventors of the present invention also provide method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, adjusting pH, diluting, sterilization by aseptic filtration followed by heat treatment.
- the main objective of the present invention is to provide stable ready- to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and optionally other pharmaceutically acceptable excipients which can be infused without any prior dilutions before administration.
- Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients, wherein the solution can be infused without any prior dilutions before administration.
- Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents and aqueous vehicle as other pharmaceutically acceptable excipients.
- Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle.
- Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents and aqueous vehicle as other pharmaceutically acceptable excipients, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and solution having a pH of about 8.0 to 9.0.
- Another objective of the present invention is to provide stable ready-to-use aqueous composition of Gemcitabine or its pharmaceutically acceptable salts thereof which is physically stable at a temperature between 2° C to room temperatures and suitable to be given by intravenous route without any intervening step of reconstitution or dilution or mixing.
- Still another objective of the present invention is to provide method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration followed by heat treatment.
- Still another objective of the present invention is to provide method for the preparation of stable ready-to-use injectable infusion container formulation of Gemcitabine or pharmaceutically acceptable salt which does not contain aluminium over-pouch as secondary packaging comprising the steps of adding, dissolving, adjusting pH, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterili ation.
- Still another objective of the present invention is to provide method for the preparation of stable ready-to-use injectable formulation of Gemcitabine or pharmaceutically acceptable salt, wherein the composition is filled in infusion container followed by heat treatment.
- In yet another objective of the present invention is to provide better effect for the treatment of several forms of cancer including leukemias, lymphomas and breast cancer by administering stable ready-to-use injectable formulation of Gemcitabine or pharmaceutically acceptable salt.
- the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and optionally other pharmaceutically acceptable excipients.
- Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients, wherein the solution can be infused without any prior dilutions before administration.
- Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients.
- Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and solution having a pH of about 8.0 to 9.0.
- Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle.
- Another embodiment of the present invention provides stable ready-to-use injectable formulation of Gemcitabine or its pharmaceutically acceptable salts thereof which is physically stable at a temperature between 2°C to room temperature and which can be administered through intravenous route without any intervening step of reconstitution or dilution or mixing.
- Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable infusion container formulation comprising Gemcitabine or pharmaceutically acceptable salt, wherein sterili ation involves aseptic filtration process followed by heat treatment which avoids terminal sterilization and the infusion container does not contain an aluminium over-pouch as secondary packaging.
- Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration, followed by heat treatment.
- Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, adjusting pH, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterili ation.
- the present invention provides method for the preparation of stable ready-to-use injectable formulation comprising of Gemcitabine or its pharmaceutically acceptable salts as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as pharmaceutically acceptable excipients, wherein the composition is filled in infusion container followed by heat treatment.
- the present invention provides a stable ready-to-use injectable formulation comprising:
- the present invention provides a stable ready-to-use injectable formulation comprising:
- Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable formulation comprising of Gemcitabine or its pharmaceutically acceptable salts comprising adding tromethamine, tonicity modifying agents in water, adding and dissolving Gemcitabine hydrochloride, adjusting pH to 8.0 to 9.0 using pH adjusting agents, diluting with remaining amount of water, adjusting the pH, sterilization by aseptic filtration followed by heat treatment.
- the present invention provides method for the preparation of stable ready-to-use injectable formulation comprising: (a) adding tromethamine and tonicity modifying agents to 80% of water and stirred to get a clear solution,
- step (b) adding Gemcitabine hydrochloride to obtained solution of step (a) under stirring until it dissolves,
- step (c) adjusting pH of obtained solution of step (b) to 8.0 to 9.0 using pH adjusting agents
- step (e) adjusting pH of stable solution of step (d) to 8.0 to 9.0 with pH adjusting agents, if required, (f) filtering the solution aseptically through Nylon 66 Filter (0.2 micron) and filled into the stoppered glass container, and
- the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, trometh amine as stabilizing and pH modifying agent, optionally other pharmaceutically acceptable excipients.
- the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients.
- the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and solution having a pH of about 8.0 to 9.0.
- the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle.
- Stable ready-to-use formulation includes injectable formulation suitable for administration to patient.
- a ‘stable aqueous composition’ is intended to refer to a solution which when stored at a temperature in the range of 2°C to room temperature, for a period of time, is physically stable i.e. it does not show the appearance of any visible particulates, crystals and is also chemically stable.
- chemically stable means that the impurities those resulting from chemical reaction in solution remains within acceptable limits during storage period at a temperature in the range of 2°C to room temperature.
- Preferably used stabilizing and pH modifying agent is Tris(hydroxymethyl)aminomethane shown in formula (I) which is also referred to as TRIS, tromethamine and trisamine. It is a primary amine and a weak base with a pKa of 8.07 at 25°C.
- the concentration of tromethamine used in stable ready-to-use injectable formulation is from 0.001 to 1.21 % (w/v) and most preferably used concentration of trometh amine is from 0.003 to 0.12 % (w/v).
- tonicity agents as used herein is to modulate the tonicity of the formulation.
- the formulation can be hypotonic, isotonic or hypertonic.
- An isotonic solution can have an osmolality of about 250-350 mOsmol/kg.
- tonicity adjusting agents includes but not limited to sodium chloride, calcium chloride, magnesium chloride, sodium lactate, glucose, fructose, sorbitol, mannitol, galactose, inositol, maltitol, lactose, trehalose, maltose, sucrose, dextran or organic solvents such as ethanol, glycerine, sorbitol, propylene glycol or combinations thereof.
- Preferred used tonicity adjusting agent is sodium chloride or glycerine.
- the concentration of tonicity adjusting agents used in stable ready- to-use injectable formulation is from 0.25 to 3.0% (w/v).
- pH modifying agents used in the present invention includes but not limited to inorganic acids and bases, such as sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, phosphorous acid, carbonic acid, sulfurous acid, nitrous acid, ascorbic acid, propionic acid, lactic acid, citric acid, formic acid, oxalic acid, benzoic acid, acetic acid, tartaric acid, malonic acid, maleic acid, pyruvic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, sodium hydroxide, calcium hydroxide, potassium hydroxide and magnesium hydroxide, sodium dihydrogen phosphate and its hydrates, sodium phosphate and its hydrates, disodium hydrogen phosphate and its hydrates, disodium sulfate, sodium hydrogen sulfate, sodium sulfite, calcium sulfite, magnesium sulfit
- the pH of the solution is adjusted with hydrochloric acid, phosphoric acid, sulfuric acid, sodium hydroxide, sodium phosphate and their hydrates, sodium hydrogen phosphate and its hydrates, disodium hydrogen phosphate and its hydrates, acetic acid, lactic acid, citric acid.
- Most preferably used pH modifying agents are sodium hydroxide and hydrochloric acid.
- Sufficient quantity of pH adjusting agents can be used to adjust pH to 8.0 to 9.0
- ready to be infused solution of Gemcitabine or its pharmaceutically acceptable salts can be filled in suitable large volume single compartment container.
- Suitable compartment containers include, for example, glass or polymeric vials which is devoid of aluminium over-pouch, ampoules, syringes, infusion bottles with sizes ranging from 20 ml to 500 ml.
- the present invention provides a ready to be infused sterile solution which undergoes sterilization by heat treatment.
- the present invention provides the use of aseptic filtration followed by heat treatment to destroy all viable microorganisms within the final, sealed container.
- the present invention provides method for the preparation of stable ready-to- use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration followed by heat treatment.
- the present invention provides method for the preparation of stable ready-to- use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, adjusting pH, diluting, sterilizing by aseptic filtration followed by heat treatment which avoids terminal sterili ation.
- the gemcitabine or its pharmaceutically acceptable salts solution composition of the present invention undergo Heat treatment at a temperature ranging from 95° C to 105° C and more preferably from 100° C to 105°C for a period of time ranging from 45 to 90 minutes, preferably 50 to 80 minutes, and more preferably 60 minutes.
- Hear treatment is preferably carried out in the temperature range of 100° C. to 105°C for a period of time 60 minutes.
- the ready to be infused solution of all examples was sterilized by aseptic filtration (without Heat treatment) as well as by aseptic filtration followed by Heat treatment.
- the filtered solution was filled in infusion bottle.
- the filled bottles were stored at 2-8° C and 20-25°C.
- the solutions were evaluated for the physical stability i.e. presence of crystals or particulate matter. The solutions were observed regularly over a period of 6 months. Results of physical stability are given below table 1:
- Table 1 Physical stability of Ready to use Gemcitabine Injection of the present invention and of Reference Example product after 6 months of storage: The above data shows that the ready to use solution of Gemcitabine or its pharmaceutically acceptable salts are chemically and physically stable at 2-8°C as well as at room temperature. There was no observation of crystals formation or precipitation of gemcitabine ready-to-use solution which were prepared by using trometh amine as stabilizing and pH modifying agent, whereas conventional formulation prepared by tonicity modifying agents showed presence of crystals or particulate matter after 1 month when stored at 2-8°C.
- stabilizing agent has played an important role in prevention of crystallization of Gemcitabine or its pharmaceutically acceptable salts and depict its need in formulation to prevent crystallization of Gemcitabine or its pharmaceutically acceptable salts during storage period, particularly at refrigerated condition.
- the combination of Heat treatment and aseptic filtration will increase the sterility assurance level of the product.
- the inventors of present invention believe that the stabilizing and pH modifying agent Trometh amine will improve solubility Gemcitabine or its pharmaceutically acceptable salts and prevent its crystallization during storage period.
- Table 2 Stability results of Ready to use Gemcitabine Injection, 10 mg/mL, 100 mL Fill volume & Pack; 100 mL Vial (Example 1)
- NLT Not Less Than
- NMT Not More Than
- BDL Below Detection Limit
Abstract
The present invention relates to stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients which can be infused without any prior dilutions before administration. The present invention also relates to stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and tonicity adjusting agent, pH adjusting agents, and aqueous vehicle as other pharmaceutically acceptable excipients. The present invention more specifically relates to method for the preparation of stable ready-to-use injectable infusion container formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, pH adjusting, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterilization and filled into the infusion container which does not contain aluminium over-pouch as secondary packaging.
Description
A STABLE READY-TO-USE INJECTABLE COMPOSITION OF GEMCIT ABINE OR ITS SALT AND METHODS FOR PRODUCING SAME
FIELD OF INVENTION The present invention relates to stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients which can be infused without any prior dilutions before administration.
The present invention also relates to stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, trometh amine as stabilizing and pH modifying agent and tonicity adjusting agent, pH adjusting agents, and aqueous vehicle as other pharmaceutically acceptable excipients.
The present invention specifically relates to method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration followed by heat treatment.
The present invention more specifically relates to method for the preparation of stable ready-to-use injectable infusion container formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, pH adjusting, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterilization and filled into the infusion container which does not contain aluminium over-pouch as secondary packaging.
BACKGROUND OF INVENTION
Lyophilization or freeze-drying is often used to stabilize various pharmaceutical products, including virus vaccines, protein and peptide formulations,
liposome and small-chemical drug formulation. Lyophilized formulations have to be reconstituted, usually by injecting diluent through the septum into the vial. The solution is drawn up into a new syringe, the needle changed before finally being injected into the patient. These multiple steps make the lyophilized formulation inconvenient for use and provide risk of microbiological contamination during aseptic handling.
It is particularly desirable if the stable pharmaceutical composition can be prepared without the use of freeze drying techniques. A stable ready-to-use injectable solution could be stored at room temperature and the composition provides easier, safer handling, storage and distribution.
Compounds administered by infusion must be in a form ready to be dissolved (if solid) or diluted (if liquid) in an infusion liquid, or be provided as ready for infusion. Solid formulations must be such that the entire contents are readily soluble leaving essentially no solid particles and providing the entire active ingredient as homogeneously dissolved compound.
Gemcitabine is known as difluorodeoxycytidine, an analogue of cytosine arabinoside (ara-C) is a pyrimidine antimetabolite and it works by blocking the creation of new DNA, which results in cell death. Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity which is used as chemotherapy medication to treat a number of types of cancers which include breast cancer, ovarian cancer, non- small cell lung cancer, pancreatic cancer, and bladder cancer.
Chemically, Gemcitabine is 4-amino- l-(2-deoxy-2, 2-difluoro-b-D-erythro- pentofuranosyl)pyrimidin-2(lH)-one, and has the following structural formula:
Gemcitabine free base has a molecular formula of
and its hydrochloride salt having molecular formula of
Gemcitabine is a white to off-white crystalline powder which melts at 287- 292°C and is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents. The aqueous solubility of gemcitabine hydrochloride in purified water is 70.2 mg/mL. Conventional formulations of Gemcitabine hydrochloride consists of sodium chloride as tonicity adjuster and pH adjusting agents. This formulation is clear, colourless, sterile solution in a single-dose, premixed intravenous large volume infusion bags with an aluminium over-pouch as secondary packaging and terminally sterilized by autoclave process at 121°C for 15 minutes.
The recommended dose for Gemcitabine is 1 g/m of body surface area and gemcitabine can be used cytostatically in the therapeutic treatment of various types of cancer. The administration of Gemcitabine to treat different types of cancer conditions is effected intravenously, in which case the active substance must be in the form of a solution.
Some patent literature describes the stable ready-to-use formulations of Gemcitabine or its pharmaceutically acceptable salt comprising pH modifying agents and tonicity adjusting agents such as sodium chloride and/or solubilizer such as propylene glycol, wherein the solution composition is sterilized by filtration sterilization.
Chinese patent No. CN 1302782 C discloses Gemcitabine hydrochloride injection solution comprising Gemcitabine hydrochloride, a solvent for injection, a stabili er and an isotonic agent, wherein the injection pH range is in between 3.6-7.5. European Pat. No. EP 1 479 388 B1 discloses pharmaceutical composition including gemcitabine in the form of a ready-to-use solution concentrate, wherein the gemcitabine is dissolved in a mixture of water and at least one other physiologically acceptable solvent or solubilising agent, wherein solubilising agents are ethanol, polyethylene glycol 200 - 600 and/or 1,2-propanediol (propylene glycol). The pH of the composition is in the range of 3.5 to 10.0 and gemcitabine concentration is 50 mg/ml or 80 mg/ml and solution sterilized by filtration.
European Pat. No. EP 1 479 389 B1 discloses Gemcitabine ready-to-use solution comprising 0.05 mg/ml to 16.0 mg/ml of Gemcitabine having pH of above 3.5. The stability data of examples disclosed in this patent demonstrate that compositions with higher concentration of Gemcitabine (more than 16.0 mg/ml) cause precipitation when stored at lower temperatures. The solvent was selected from the ethyl alcohol, polyethylene glycol 200-600, propylene glycol and mixture thereof. Solution is sterilized by filtration and the filtered solution is filled into vials.
U.S Pat. No. 9,241,948 B2 discloses large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion polymeric container covered with a secondary packaging system of aluminium over-pouch, wherein the solution is ready-to-be-infused. The injection dosage form is obtained by subjecting the solution filled in infusion container to terminal sterili ation by autoclave at 121°C for 15 minutes.
U.S Pub No. US 2006/0089328 A1 discloses an injectable pharmaceutical composition comprising a solution of gemcitabine or its salt in a solvent having a pH
of about 3.5 to about 10 and a gemcitabine concentration of about 0.5 mg/ml to about 16 mg/ml, wherein solvent is selected from the group consisting of water, ethyl alcohol, polyethylene glycol 200-600, and propylene glycol and mixtures thereof. Solution was sterilized by filtration and filled in stoppered vials.
U.S Pub No. US 2006/0154891 A1 discloses ready-to-use Gemcitabine aqueous preparation in glass container having specified dimensional relationships to demonstrate shelf life of over wide range of solution pH values. The ratio of surface area wetted by the composition to the volume of the solution contained in the container, expressed in cm /cm is less than 3.4. Gemcitabine concentration is between 0.05 mg/mL and 110 mg/mL and pH of the aqueous solution is within a range of about 5.0 to about 10.0.
U.S Pub No. US 2012/0129799 A1 discloses stable non-aqueous pharmaceutical preparation comprising Gemcitabine or its pharmaceutically acceptable salts in a ready-to-use form comprising non-aqueous solvent, wherein non- aqueous solvent includes propylene glycol, polyethylene glycols, ethanol or the like thereof either alone or in combination thereof and the pH is between about 3.5 and about 10.0.
PCT Pub No. WO 2007/143895 A1 discloses, stable supersaturated solution of Gemcitabine hydrochloride, which is prepared by dissolving completely Gemcitabine hydrochloride in a medium by heating it at pH 4-8 to give a supersaturated solution of Gemcitabine having a concentrate of 15-45 g/L and the hot supersaturated solution was sterilized by filtration and dispensed in ampoules.
Patrick J. Jansen et al. , The Journal of Pharmaceutical Sciences, 2000, vol. 89, No.7, Pg. No. 885-891, discloses the Gemcitabine aqueous solution. Sodium acetate was used to adjust pH of solution to 3.2. However degradation of Gemcitabine in aqueous solution at pH 3.2 indicates that development of formulation was feasible
when stored at refrigerated temperature. However, at thermally stressed conditions caused significant degradation of products.
The commercially available product contain Gemcitabine or its pharmaceutically salt and is marketed under the trade name Gemzar® by Eli Lilly & Co which is supplied as a sterile lyophilised powder in single-dose vials for reconstitution which has to be dissolved for intravenous infusion. The product formulation contains, in addition to the active ingredient, mannitol, sodium acetate and hydrochloric acid and / sodium hydroxide may have been added for pH adjustment. Gemzar® upon reconstitution, concentration is 40 mg/mL. It is reported that at concentrations greater than 40 mg/mL may result in incomplete dissolution, and therefore should be avoided.
It was discovered that a simple, isotonic saline solution of gemcitabine is not pharmaceutically acceptable for commercial purposes due to degradation of the solution to form unacceptable related substances. The chemical instability of gemcitabine is mainly attributed to their hydrolytic degradation. Hence, the main challenge lies in formulating a stable pharmaceutical composition of gemcitabine that has the minimum concentration of hydrolytic degradation impurities.
A ready-to-use solution can be filled in vial or glass container and supplied as single dose vial. Sterilization of injectable solution filled in the glass container plays a major role in maintaining stability and shelf life of the drug product. Sterilization of glass container can be achieved by many ways either by filtration sterilization, terminal sterilization by moist heat and dry heat sterilization. Hence, the use of stabilizer in the formulation and sterilization of infusion container are the key elements in developing a stable pharmaceutical composition of Gemcitabine or its salt.
Thus to overcome drawbacks associated with currently available formulation like precipitation issues including stability and solubility of ready-to-use Gemcitabine
solution, there is a need to develop a stable ready-to-be-infused preparation containing Gemcitabine or its pharmaceutically acceptable salts. The inventors of the present invention have developed a stable ready-to-use injectable Gemcitabine composition comprising tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents as other pharmaceutically acceptable excipients which provide better effect for the treatment of several forms of cancer including leukemias, lymphomas and breast cancer. The inventors of the present invention also provide method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, adjusting pH, diluting, sterilization by aseptic filtration followed by heat treatment.
OBJECTIVE OF INVENTION
The main objective of the present invention is to provide stable ready- to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and optionally other pharmaceutically acceptable excipients which can be infused without any prior dilutions before administration.
Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients, wherein the solution can be infused without any prior dilutions before administration.
Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents and aqueous vehicle as other pharmaceutically acceptable excipients.
Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle.
Another objective of the present invention is to provide stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents and aqueous vehicle as other pharmaceutically acceptable excipients, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and solution having a pH of about 8.0 to 9.0. Another objective of the present invention is to provide stable ready-to-use aqueous composition of Gemcitabine or its pharmaceutically acceptable salts thereof which is physically stable at a temperature between 2° C to room temperatures and suitable to be given by intravenous route without any intervening step of reconstitution or dilution or mixing.
Still another objective of the present invention is to provide method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration followed by heat treatment.
Still another objective of the present invention is to provide method for the preparation of stable ready-to-use injectable infusion container formulation of Gemcitabine or pharmaceutically acceptable salt which does not contain aluminium over-pouch as secondary packaging comprising the steps of adding, dissolving,
adjusting pH, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterili ation.
Still another objective of the present invention is to provide method for the preparation of stable ready-to-use injectable formulation of Gemcitabine or pharmaceutically acceptable salt, wherein the composition is filled in infusion container followed by heat treatment.
In yet another objective of the present invention is to provide better effect for the treatment of several forms of cancer including leukemias, lymphomas and breast cancer by administering stable ready-to-use injectable formulation of Gemcitabine or pharmaceutically acceptable salt.
SUMMARY OF INVENTION
Accordingly, the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and optionally other pharmaceutically acceptable excipients.
Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent and other pharmaceutically acceptable excipients, wherein the solution can be infused without any prior dilutions before administration.
Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients.
Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and solution having a pH of about 8.0 to 9.0.
Another embodiment of the present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle. Another embodiment of the present invention provides stable ready-to-use injectable formulation of Gemcitabine or its pharmaceutically acceptable salts thereof which is physically stable at a temperature between 2°C to room temperature and which can be administered through intravenous route without any intervening step of reconstitution or dilution or mixing.
Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable infusion container formulation comprising Gemcitabine or pharmaceutically acceptable salt, wherein sterili ation involves aseptic filtration process followed by heat treatment which avoids terminal sterilization and the infusion container does not contain an aluminium over-pouch as secondary packaging.
Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or
pharmaceutically acceptable salt which involves sterilization by aseptic filtration, followed by heat treatment.
Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, adjusting pH, diluting, sterilization by aseptic filtration followed by heat treatment which avoids terminal sterili ation.
In another embodiment, the present invention provides method for the preparation of stable ready-to-use injectable formulation comprising of Gemcitabine or its pharmaceutically acceptable salts as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as pharmaceutically acceptable excipients, wherein the composition is filled in infusion container followed by heat treatment.
In another embodiment, the present invention provides a stable ready-to-use injectable formulation comprising:
(a) 0.1% to 1% (w/v) of Gemcitabine or its salt,
(b) 0.001% to 1.21% (w/v) of tromethamine,
(c) 0.25% to 3% (w/v) of tonicity adjusting agents,
(d) pH adjusting agents to adjust pH, and
(e) aqueous vehicle.
In yet another embodiment, the present invention provides a stable ready-to-use injectable formulation comprising:
(a) 0.1% to 1% (w/v) of Gemcitabine or its salt,
(b) 0.001% to 1.21% (w/v) of tromethamine,
(c) 0.25% to 3% (w/v) of sodium chloride or glycerine,
(d) sodium hydroxide and Hydrochloric acid as pH adjusting agents to adjust pH to 8.0 to 9.0, and
(e) water for injection. Another embodiment of the present invention provides method for the preparation of stable ready-to-use injectable formulation comprising of Gemcitabine or its pharmaceutically acceptable salts comprising adding tromethamine, tonicity modifying agents in water, adding and dissolving Gemcitabine hydrochloride, adjusting pH to 8.0 to 9.0 using pH adjusting agents, diluting with remaining amount of water, adjusting the pH, sterilization by aseptic filtration followed by heat treatment.
In yet another embodiment, the present invention provides method for the preparation of stable ready-to-use injectable formulation comprising: (a) adding tromethamine and tonicity modifying agents to 80% of water and stirred to get a clear solution,
(b) adding Gemcitabine hydrochloride to obtained solution of step (a) under stirring until it dissolves,
(c) adjusting pH of obtained solution of step (b) to 8.0 to 9.0 using pH adjusting agents,
(d) diluting the solution with remaining amount of water to get a stable solution,
(e) adjusting pH of stable solution of step (d) to 8.0 to 9.0 with pH adjusting agents, if required, (f) filtering the solution aseptically through Nylon 66 Filter (0.2 micron) and filled into the stoppered glass container, and
(g) heat treatment at a temperature of 100°C to 105°C for a period of time ranging from 30 to 60 minutes after final packaging.
DETAILED DESCRIPTION OF THE INVENTION
The term "comprising", which is synonymous with "including", "containing", or "characterized by" here is defined as being inclusive or open-ended, and does not exclude additional, unrecited elements or method steps, unless the context clearly requires otherwise.
The present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, trometh amine as stabilizing and pH modifying agent, optionally other pharmaceutically acceptable excipients.
The present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients.
The present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and solution having a pH of about 8.0 to 9.0.
The present invention provides stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, tromethamine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle.
"Stable ready-to-use formulation” of the present invention includes injectable formulation suitable for administration to patient. In particular, a ‘stable aqueous composition’ is intended to refer to a solution which when stored at a temperature in the range of 2°C to room temperature, for a period of time, is physically stable i.e. it does not show the appearance of any visible particulates, crystals and is also chemically stable.
The term ‘chemically stable’ as used herein means that the impurities those resulting from chemical reaction in solution remains within acceptable limits during storage period at a temperature in the range of 2°C to room temperature.
Preferably used stabilizing and pH modifying agent is Tris(hydroxymethyl)aminomethane shown in formula (I) which is also referred to as TRIS, tromethamine and trisamine. It is a primary amine and a weak base with a pKa of 8.07 at 25°C.
The concentration of tromethamine used in stable ready-to-use injectable formulation is from 0.001 to 1.21 % (w/v) and most preferably used concentration of trometh amine is from 0.003 to 0.12 % (w/v).
The term "tonicity agents" as used herein is to modulate the tonicity of the formulation. The formulation can be hypotonic, isotonic or hypertonic. An isotonic solution can have an osmolality of about 250-350 mOsmol/kg.
The term “tonicity adjusting agents” as used in the present invention includes but not limited to sodium chloride, calcium chloride, magnesium chloride, sodium lactate, glucose, fructose, sorbitol, mannitol, galactose, inositol, maltitol, lactose, trehalose, maltose, sucrose, dextran or organic solvents such as ethanol, glycerine, sorbitol, propylene glycol or combinations thereof. Preferred used tonicity adjusting agent is sodium chloride or glycerine.
The concentration of tonicity adjusting agents used in stable ready- to-use injectable formulation is from 0.25 to 3.0% (w/v).
The term “pH modifying agents” used in the present invention includes but not limited to inorganic acids and bases, such as sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, phosphorous acid, carbonic acid, sulfurous acid, nitrous acid, ascorbic acid, propionic acid, lactic acid, citric acid, formic acid, oxalic acid, benzoic acid, acetic acid, tartaric acid, malonic acid, maleic acid, pyruvic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, sodium hydroxide, calcium hydroxide, potassium hydroxide and magnesium hydroxide, sodium dihydrogen phosphate and its hydrates, sodium phosphate and its hydrates, disodium hydrogen phosphate and its hydrates, disodium sulfate, sodium hydrogen sulfate, sodium sulfite, calcium sulfite, magnesium sulfite, sodium carbonate, sodium hydrogen carbonate, calcium hydrogen carbonate, sodium nitrite, sodium nitrate, magnesium nitrate, calcium nitrite and magnesium nitrite, 1-deoxy- (methylamino)-D-glucitol (N-methylglucamine, meglumine). Preferably, the pH of the solution is adjusted with hydrochloric acid, phosphoric acid, sulfuric acid, sodium hydroxide, sodium phosphate and their hydrates, sodium hydrogen phosphate and its hydrates, disodium hydrogen phosphate and its hydrates, acetic acid, lactic acid, citric acid. Most preferably used pH modifying agents are sodium hydroxide and hydrochloric acid. Sufficient quantity of pH adjusting agents can be used to adjust pH to 8.0 to 9.0
According to the present invention ready to be infused solution of Gemcitabine or its pharmaceutically acceptable salts can be filled in suitable large volume single compartment container. Suitable compartment containers include, for example, glass or polymeric vials which is devoid of aluminium over-pouch, ampoules, syringes, infusion bottles with sizes ranging from 20 ml to 500 ml.
The present invention provides a ready to be infused sterile solution which undergoes sterilization by heat treatment. Particularly, the present invention provides the use of aseptic filtration followed by heat treatment to destroy all viable microorganisms within the final, sealed container.
The present invention provides method for the preparation of stable ready-to- use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt which involves sterilization by aseptic filtration followed by heat treatment.
The present invention provides method for the preparation of stable ready-to- use injectable infusion formulation of Gemcitabine or pharmaceutically acceptable salt comprising the steps of adding, dissolving, adjusting pH, diluting, sterilizing by aseptic filtration followed by heat treatment which avoids terminal sterili ation.
The gemcitabine or its pharmaceutically acceptable salts solution composition of the present invention undergo Heat treatment at a temperature ranging from 95° C to 105° C and more preferably from 100° C to 105°C for a period of time ranging from 45 to 90 minutes, preferably 50 to 80 minutes, and more preferably 60 minutes. In particular, Hear treatment is preferably carried out in the temperature range of 100° C. to 105°C for a period of time 60 minutes.
The following examples describes the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not
limitative and relate to solutions which have been particularly effective on a bench scale and prepared by the process of the present invention.
Manufacturing process for preparation of readv-to-use solution of Gemcitabine
Hydrochloride: Trometh amine and tonicity modifying agents were added to 80% of water and stirred to get a clear solution. Gemcitabine hydrochloride is added and stirred until the mixture dissolves. pH was adjusted to 8.0 to 9.0 with pH adjusting agents like sodium hydroxide and hydrochloric acid. The solution was further diluted with remaining amount of water to get a stable solution. pH was adjusted, if required. The solution was filtered aseptically through Nylon 66 Filter (0.2 micron) and undergone heat treatment at a temperature of 100°C to 105°C for a period of time ranging from 30 to 60 minutes and obtained solution of Gemcitabine filled into the stoppered glass containers and final packaging. The ready to be infused solution of all examples was sterilized by aseptic filtration (without Heat treatment) as well as by aseptic filtration followed by Heat treatment. The filtered solution was filled in infusion bottle. The filled bottles were stored at 2-8° C and 20-25°C. The solutions were evaluated for the physical stability i.e. presence of crystals or particulate matter. The solutions were observed regularly over a period of 6 months. Results of physical stability are given below table 1:
Manufacturing process for preparation of conventional readv-to-use solution of Gemcitabine Hydrochloride: Tonicity modifying agents were added to 80% of water and stirred to get a clear solution. Gemcitabine hydrochloride is added and stirred until the mixture dissolves. pH was adjusted to 8.0 to 9.0 with pH adjusting agents like sodium hydroxide and hydrochloric acid. The solution was further diluted with remaining amount of water to get a stable solution. pH was adjusted, if required. The solution was sterilized by aseptic filtration (without heat treatment) using Nylon 66 Filter (0.2 micron) and filled into the stoppered glass container.
Table 1: Physical stability of Ready to use Gemcitabine Injection of the present invention and of Reference Example product after 6 months of storage:
The above data shows that the ready to use solution of Gemcitabine or its pharmaceutically acceptable salts are chemically and physically stable at 2-8°C as well as at room temperature. There was no observation of crystals formation or precipitation of gemcitabine ready-to-use solution which were prepared by using trometh amine as stabilizing and pH modifying agent, whereas conventional formulation prepared by tonicity modifying agents showed presence of crystals or particulate matter after 1 month when stored at 2-8°C. Thus, the use of stabilizing agent has played an important role in prevention of crystallization of Gemcitabine or its pharmaceutically acceptable salts and depict its need in formulation to prevent crystallization of Gemcitabine or its pharmaceutically acceptable salts during storage period, particularly at refrigerated condition. The combination of Heat treatment and aseptic filtration will increase the sterility assurance level of the product. The inventors of present invention believe that the stabilizing and pH modifying agent Trometh amine will improve solubility Gemcitabine or its pharmaceutically acceptable salts and prevent its crystallization during storage period.
Finished product was stored at different stability conditions as per ICH guideline. The initial sample of ready to use solution and samples stored at different stability conditions were analysed for assay, related substance (%), pH, absorbance at 420nm, % transmittance at 650 nm and osmolality. The solution is chemically stable having impurity levels within the acceptable pharmacopoeial and ICH limits. The results of the representative examples are given in Table 2 and Table 3.
Table 2: Stability results of Ready to use Gemcitabine Injection, 10 mg/mL, 100 mL Fill volume & Pack; 100 mL Vial (Example 1)
NLT: Not Less Than, NMT: Not More Than, BDL: Below Detection Limit
Claims
1. A stable ready-to-use injectable formulation comprising Gemcitabine or pharmaceutically acceptable salt, trometh amine as stabilizing and pH modifying agent and optionally other pharmaceutically acceptable excipients.
2. The stable ready-to-use injectable formulation as claimed in claim 1, wherein the solution can be infused without any prior dilutions before administration.
3. The stable ready-to-use injectable formulation as claimed in claims 1 and 2 which is stable at a temperature between 2°C to room temperature.
4. The stable ready-to-use injectable formulation as claimed in claims 1 to 3, wherein concentration of tromethamine used in stable ready-to-use injectable formulation is from 0.001 to 1.21 % (w/v) and most preferably used concentration of tromethamine is from 0.003 to 0.12 % (w/v).
5. The stable ready-to-use injectable formulation as claimed in claims 1 to 4, wherein the formulation comprise tonicity adjusting agents, pH modifying agents, aqueous vehicle as other pharmaceutically acceptable excipients.
6. The stable ready-to-use injectable formulation as claimed in claim 5, wherein the tonicity adjusting agent is selected from sodium chloride, calcium chloride, magnesium chloride, sodium lactate, glucose, fructose, sorbitol, mannitol, galactose, inositol, maltitol, lactose, trehalose, maltose, sucrose, dextran or organic solvents such as ethanol, glycerine, sorbitol, propylene glycol or combinations thereof.
7. The stable ready-to-use injectable formulation as claimed in claim 6, wherein the concentration of tonicity adjusting agents used in stable ready-to-use injectable formulation is from 0.25 to 3.0% (w/v).
8. The stable ready-to-use injectable formulation as claimed in claim 3, wherein the pH modifying agent is selected from inorganic acids and bases, such as sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, phosphorous acid, carbonic acid, sulfurous acid, nitrous acid, ascorbic acid, propionic acid, lactic acid, citric acid, formic acid, oxalic acid, benzoic acid, acetic acid, tartaric acid, malonic acid, maleic acid, pyruvic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, sodium hydroxide, calcium hydroxide, potassium hydroxide and magnesium hydroxide, sodium dihydrogen phosphate and its hydrates, sodium phosphate and its hydrates, disodium hydrogen phosphate and its hydrates, disodium sulfate, sodium hydrogen sulfate, sodium sulfite, calcium sulfite, magnesium sulfite, sodium carbonate, sodium hydrogen carbonate, calcium hydrogen carbonate, sodium nitrite, sodium nitrate, magnesium nitrate, calcium nitrite and magnesium nitrite, 1- deoxy-(methylamino)-D-glucitol (N-methylglucamine, meglumine).
9. The stable ready-to-use injectable formulation as claimed in claims 1 to 8, wherein the concentration of Gemcitabine or its pharmaceutically acceptable salts is 10 mg/ml and the solution having a pH of about 8.0 to 9.0.
10. A stable ready-to-use injectable formulation as claimed in claims 1 to 9, wherein the formulation comprising:
(a) 0.1% to 1% (w/v) of Gemcitabine or its salt,
(b) 0.001% to 1.21% (w/v) of tromethamine as stabilizing and pH modifying agent,
(c) 0.25% to 3% (w/v) of tonicity adjusting agents, (d) quantity sufficient of pH adjusting agents, and
(e) aqueous vehicle.
11. The stable ready-to-use injectable formulation as claimed in claims 1 to 10, wherein the formulation comprising Gemcitabine or pharmaceutically acceptable salt as active ingredient, trometh amine as stabilizing and pH modifying agent, sodium chloride or glycerine as tonicity adjusting agents, sodium hydroxide and hydrochloric acid as pH adjusting agents and water for injection as aqueous vehicle.
12. The stable ready-to-use injectable formulation as claimed in claims 1 to 10, wherein the infusion container does not contain an aluminium over-pouch as secondary packaging.
13. A method for the preparation of stable ready-to-use injectable infusion container formulation comprising Gemcitabine or pharmaceutically acceptable salt, wherein sterilization involves aseptic filtration process followed by heat treatment which avoids terminal sterili ation.
14. The method for the preparation of stable ready-to-use injectable formulation as claimed in claim 13, wherein the method comprise:
(a) adding tromethamine and tonicity modifying agents to 80% of water and stirred to get a clear solution,
(b) adding Gemcitabine hydrochloride to obtained solution of step (a) under stirring until it dissolves, (c) adjusting pH of obtained solution of step (b) to 8.0 to 9.0 using pH adjusting agents,
(d) diluting the solution with remaining amount of water to get a stable solution,
(e) adjusting pH of stable solution of step (d) to 8.0 to 9.0 with pH adjusting agents, if required,
(f) filtering the solution aseptically through Nylon 66 Filter (0.2 micron) and filled into the stoppered glass container, and
(g) heat treatment at a temperature of 100°C to 105°C for a period of time ranging from 30 to 60 minutes after final packaging.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941032689 | 2019-08-13 | ||
IN201941032689 | 2019-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021028842A1 true WO2021028842A1 (en) | 2021-02-18 |
Family
ID=74570964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/057570 WO2021028842A1 (en) | 2019-08-13 | 2020-08-12 | A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021028842A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060154891A1 (en) * | 2004-12-23 | 2006-07-13 | Edgar Schridde | Ready-to-use gemcitabine solutions and gemcitabin concentrates |
WO2011016049A2 (en) * | 2009-07-31 | 2011-02-10 | Astron Research Limited | A stable composition of ready-to-use gemcitabine injection |
WO2013171763A1 (en) * | 2012-04-27 | 2013-11-21 | Sun Pharmaceutical Industries Ltd | Ready to be infused gemcitabine solution |
-
2020
- 2020-08-12 WO PCT/IB2020/057570 patent/WO2021028842A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060154891A1 (en) * | 2004-12-23 | 2006-07-13 | Edgar Schridde | Ready-to-use gemcitabine solutions and gemcitabin concentrates |
WO2011016049A2 (en) * | 2009-07-31 | 2011-02-10 | Astron Research Limited | A stable composition of ready-to-use gemcitabine injection |
WO2013171763A1 (en) * | 2012-04-27 | 2013-11-21 | Sun Pharmaceutical Industries Ltd | Ready to be infused gemcitabine solution |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6900184B2 (en) | Compositions containing pipercillin and tazobactam useful for injection | |
US20060154891A1 (en) | Ready-to-use gemcitabine solutions and gemcitabin concentrates | |
US8975284B2 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
NO335045B1 (en) | Pharmaceutical formulations of temozolomide, processes for their preparation, lyophilized powder of the formulations, prepared article containing the lyophilized powder, and use of the formulations as a drug | |
JP6942182B2 (en) | Parenteral drug formulation containing calglumic acid | |
BRPI0616127B1 (en) | Aqueous, sterile, stable, injectable pharmaceutical solution and its method of preparation | |
EP2094308B1 (en) | Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure | |
JP2016521731A (en) | Stable water-soluble pharmaceutical composition containing anticancer agent | |
CZ298581B6 (en) | Pharmaceutically stable oxaliplatin preparation for parenteral administration | |
JP6818019B2 (en) | Injectable pharmaceutical composition of lefamulin | |
US11654154B2 (en) | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability | |
JP2011137048A (en) | Pharmaceutical preparation for new use, as well as process for production of the same | |
US20120283304A1 (en) | Formulations of Temozolomide for Parenteral Administration | |
WO2002002125A1 (en) | Injectable composition | |
EP3308770A1 (en) | Pemetrexed formulation | |
WO2021028842A1 (en) | A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same | |
ES2215856T3 (en) | SOLUTION OF MONOSODIC SALT TETRAHYDRATE OF N- (O- (P-PIVALOYLOXIBENCENO-SULFONYLAMINE) BENZOIL) GLYCINE AND MEDICINAL PRODUCT CONTAINING THIS SOLUTION. | |
KR20030016426A (en) | FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME | |
JP7423028B2 (en) | Lyophilized pharmaceutical composition containing bortezomib | |
KR101487953B1 (en) | Organic solvent-free aqueous solution composition of gemcitabine | |
WO2023214433A1 (en) | Stable parenteral compositions of parecoxib | |
JP6033931B2 (en) | Organic solvent-free gemcitabine aqueous solution composition | |
EP3220954A2 (en) | Process for preparation of parenteral formulation of anidulafungin | |
EP2976063A1 (en) | Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof | |
JP2015000869A (en) | Organic solvent-free gemcitabine aqueous solution composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20852085 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20852085 Country of ref document: EP Kind code of ref document: A1 |